Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects

被引:0
|
作者
Pandey, Swaroop Kumar [1 ]
Yadav, Neha [2 ]
Mishra, Anuja [1 ]
Sohal, Jagdip Singh [3 ]
Thakur, Komal [3 ]
Dwivedi-Agnihotri, Hemlata [2 ]
机构
[1] GLA Univ, Inst Appl Sci & Humanities, Dept Biotechnol, Mathura 281406, India
[2] Univ Delhi, Dept Biophys, South Campus, New Delhi 110021, India
[3] GLA Univ, Ctr Vaccine & Diagnost Res, Mathura, India
关键词
Pleura; mesothelioma; socioeconomic burden; asbestos; carbon nanotubes; INTENSITY-MODULATED RADIOTHERAPY; PHASE-II TRIAL; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; INTERVENTION SITES; ASBESTOS BAN; OPEN-LABEL; MULTICENTER; RADIATION; IMMUNOTHERAPY;
D O I
10.2174/0115733947315242240718074626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pleural malignancy is an aggressive malignancy of the pleural surface and is primarily associated with asbestos exposure. Malignant pleural mesothelioma (MPM) is an invasive form of mesothelioma and resistant to conventional therapy. Recently, it has also been reported that carbon nanotube (CNTs) exposure can induce inflammation and fibrosis of the pleura and induce tumor development pre-clinical model. Although several strategies like immunotherapy (Dendritic cells, immune checkpoint inhibitors, CAR-T cell therapy), and viral therapy are being employed for the management of MPM. However, poor prognosis and limited treatment options make the problem worse. Apart from clinical challenges, industrial and socioeconomic challenges are key factors for the patients as they are mainly industry workers or their associates. This article is focused on industrial, clinical and socioeconomic challenges associated with malignant pleural mesothelioma (MPM) patients and available opportunities.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Current treatments and trials in malignant pleural mesothelioma
    Bibby, Anna C.
    Maskell, Nick A.
    CLINICAL RESPIRATORY JOURNAL, 2018, 12 (07) : 2161 - 2169
  • [32] Malignant Pleural Mesothelioma Updates for Respiratory Physicians
    Sidhu, Calvin
    Louw, Amber
    Lee, Y. C. Gary
    CLINICS IN CHEST MEDICINE, 2021, 42 (04) : 697 - 710
  • [33] Updates in the diagnosis and treatment of malignant pleural mesothelioma
    Katzman, Daniel
    Sterman, Daniel H.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (04) : 319 - 326
  • [34] The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma
    Perera, Nirosha D.
    Mansfield, Aaron S.
    CURRENT ONCOLOGY REPORTS, 2022, 24 (11) : 1413 - 1423
  • [35] European guidelines for the management of malignant pleural mesothelioma
    van Thiel, Eric
    van Meerbeeck, Jan P.
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2010, 120 (12): : 503 - 509
  • [36] The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
    Banerji, Shantanu
    Meyers, Daniel E.
    Harlos, Craig
    Dawe, David E.
    CURRENT ONCOLOGY, 2021, 28 (06) : 4542 - 4551
  • [37] Nivolumab plus ipilimumab in malignant pleural mesothelioma
    Travert, Camille
    Tomasini, Pascale
    Greillier, Laurent
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 815 - 822
  • [38] Progress in the Management of Malignant Pleural Mesothelioma in 2017
    McCambridge, Amanda J.
    Napolitano, Andrea
    Mansfield, Aaron S.
    Fennell, Dean A.
    Sekido, Yoshitaka
    Nowak, Anna K.
    Reungwetwattana, Thanyanan
    Mao, Weimin
    Pass, Harvey I.
    Carbone, Michele
    Yang, Haining
    Peikert, Tobias
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : 606 - 623
  • [39] Targeted therapies in malignant pleural mesothelioma: a review of clinical studies
    Greillier, Laurent
    Marco, Sabine
    Barlesi, Fabrice
    ANTI-CANCER DRUGS, 2011, 22 (03) : 199 - 205
  • [40] Pemetrexed in malignant pleural mesothelioma and the clinical outcome
    Knuuttila, Aija
    Salomaa, Eija-Riitta
    Saikkonen, Suvi
    Hurme, Saija
    Salo, Jarmo
    CLINICAL RESPIRATORY JOURNAL, 2012, 6 (02) : 96 - 103